海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
32件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A trial of adding nitroglycerin tochemotherapy for advanced lung cancer
- advanced non-small cell lung cancer MedDRA version: 14.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Netherlands, New Zealand
- 2013-07-09
Authorised
- increased efficacy of lidocaine when amitriptyline is added for local anaesthesia
- The objective of the present study is to investigate whether a combination of ultra-low-dose amitriptyline with the conventional local anesthetic lidocaine enhances the anesthetic effect of the latter via pharmacologic synergy. MedDRA version: 8.1 Level: LLT Classification code 10002095 Term: Anaesthesia local
- Austria
- 2007-07-04
Authorised
- A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis
- Multiple sclerosis
- Austria, Germany, Italy, United Kingdom
- 2006-12-17
Authorised
- Clinical study in subjects with pancreatic adenocarcinoma to assess safety and efficacy of investigational product (eryaspase) when added to standard chemotherapy
- Pancreatic Adenocarcinoma MedDRA version: 20.0 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
- 2018-06-20
Authorised
- To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.
- Relapsed and/or Refractory Multiple Myeloma MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Singapore, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States
- 2012-04-24
Authorised
- Treatment of children with newly diagnosed brain tumour (known as supratentorial, infratentorial cerebellar, or peduncular high-grade glioma) using bevacizumab, an anti-angiogenic drug, added to conventional therapy (surgery, chemotherapy with temozolomide and radiation therapy).
- Newly diagnosed high-grade glioma MedDRA version: 17.0 Level: LLT Classification code 10002226 Term: Anaplastic ependymoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: LLT Classification code 10030288 Term: Oligodendroglioma malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: LLT Classification code 10027744 Term: Mixed astrocytoma-oligodendroglioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10030286 Term: Oligodendroglioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10065443 Term: Malignant glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10018338 Term: Glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10026659 Term: Malignant oligodendroglioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Hungary, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
- 2011-05-16
Authorised
- 221AD301 Phase 3 Study of Aducanumab in Early Alzheimer's Disease
- Early Alzheimer's Disease MedDRA version: 18.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Portugal, Spain, Taiwan, United Kingdom, United States
- 2015-06-03
Authorised
- 221AD302 Phase 3 Study of Aducanumab in Early Alzheimer's Disease
- Early Alzheimer's Disease MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Poland, Portugal, Spain, Sweden, Taiwan, United Kingdom, United States
- 2015-05-18
Authorised
- Pharmakokinetik von Teicoplanin bei kritisch Kranken während kontinuierlicher veno-venöser Hämofiltration und während Albumindialyse (Pharmacokinetics of teicoplanin in critically ill durining veno-venous hemofiltration and albumin dialysis) - Teicoplanin in HF and AD
- Plasma concentrations of teicoplanin will be measured in critically ill patients requirirng teicoplanin treatment for severe infection (proven or suspected infection with methicillin-resistant staphylococci) as well as continuous veno-venous hemofiltration for renal failure or albumin dialysis for cholestatic liver failure.
- Austria
- 2005-03-22
Authorised
- A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study to investigate the effects of 24 weeks of monotherapy with SB-742457 on cognition in subjects with mild to moderate Alzheimer's disease
- Alzheimer’s disease
- Austria, Czech Republic, Spain
- 2005-05-17
